Molinari Francesca, Frattini Milo
Laboratory of Molecular Pathology, Institute of Pathology , Locarno , Switzerland.
Front Oncol. 2014 Jan 16;3:326. doi: 10.3389/fonc.2013.00326. eCollection 2013.
Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene located at chromosome 10q23.31, encoding for a 403-amino acid protein that possesses both lipid and protein phosphatase activities. The main function of PTEN is to block the PI3K pathway by dephosphorylating phosphatidylinositol (PI) 3,4,5-triphosphate to PI-4,5-bisphosphate thus counteracting PI3K function. PTEN inactivation is a frequent event in many cancer types and can occur through various genetic alterations including point mutations, large chromosomal deletions, and epigenetic mechanisms. In colorectal cancer (CRC) PTEN is altered through mixed genetic/epigenetic mechanisms (typically: mutations and promoter hypermethylation or 10q23 LOH and promoter hypermethylation), which lead to the biallelic inactivation of the protein in 20-30% of cases. The role of PTEN as a prognostic and predictive factor in CRC has been addressed by relatively few works. This review is focused on the report and on the discussion of the studies investigating these aspects. Overall, at the moment, there are conflicting results and, therefore it has not been clarified whether PTEN might play a prognostic role in CRC. The same is valid also for the predictive role, leading to the fact that PTEN evaluation cannot be used in routinely diagnosis for the early identification of patients who might be addressed to the treatment with EGFR-targeted therapies, at odds with other genetic alterations belonging to EGFR-downstream pathways. The reason of discordant results may be attributable to several issues: (1) the size of the analyzed cohort, (2) patients inclusion criteria, (3) the methods of assessing PTEN alteration. In particular, there are no standardized methods to evaluate this marker, especially for immunohistochemistry, a technique suffering of intra and inter-observer variability due to the semi-quantitative character of such an analysis. In conclusion, much work, especially in large and homogeneous cohorts of cases from different laboratories, has to be done before the establishment of PTEN as prognostic or predictive marker in CRC.
10号染色体缺失的磷酸酶和张力蛋白同源物(PTEN)是一种位于10号染色体q23.31的抑癌基因,编码一种具有脂质和蛋白质磷酸酶活性的403个氨基酸的蛋白质。PTEN的主要功能是通过将磷脂酰肌醇(PI)3,4,5 - 三磷酸去磷酸化为PI - 4,5 - 二磷酸来阻断PI3K途径,从而抵消PI3K的功能。PTEN失活在许多癌症类型中是常见事件,可通过各种基因改变发生,包括点突变、大的染色体缺失和表观遗传机制。在结直肠癌(CRC)中,PTEN通过混合的遗传/表观遗传机制发生改变(通常为:突变和启动子高甲基化或10q23杂合性缺失和启动子高甲基化),这导致20% - 30%的病例中该蛋白的双等位基因失活。相对较少的研究探讨了PTEN作为CRC预后和预测因子的作用。本综述重点关注调查这些方面的研究报告和讨论。总体而言,目前结果相互矛盾,因此尚未阐明PTEN是否可能在CRC中发挥预后作用。预测作用方面情况相同,这导致PTEN评估不能用于常规诊断以早期识别可能接受表皮生长因子受体(EGFR)靶向治疗的患者,这与属于EGFR下游途径的其他基因改变不同。结果不一致的原因可能归因于几个问题:(1)分析队列的规模;(2)患者纳入标准;(3)评估PTEN改变的方法。特别是,没有标准化的方法来评估这个标志物,尤其是对于免疫组织化学,由于这种分析的半定量性质,该技术存在观察者内和观察者间的变异性。总之,在将PTEN确立为CRC的预后或预测标志物之前,还需要做很多工作,特别是在来自不同实验室的大量同质病例队列中进行研究。